Monitoring and Adjustments: Regular follow-up appointments allow for monitoring progress and making necessary adjustments to optimize results
Both ODTs and injections can cause GLP-1-related side effects such as nausea, constipation, reflux, bloating, diarrhea, reduced appetite, or fatigue
Body weight is only one measure of progress
*In a 68- and 72-week clinical trial studying Semaglutide in patients without diabetes and with BMI 30, or BMI 27 with a weight-related condition, the average weight loss was 15% and 20%, when paired with diet and exercise changes (compared to 2.4% and 3.1%, respectively, with diet and exercise alone)
Mun JG, Wang D, Doerflein Fulk DL, et al
The role of artificial intelligence in identifying depression and anxiety: a comprehensive literature review